SI-BONE (SIBN) Q1 2026 earnings review
Profitability Surges While Top-Line Growth Decelerates
SI-BONE delivered a structurally profitable quarter in 26Q1, achieving a 440% YoY improvement in adjusted EBITDA ($2.5M) and an impressive 79.8% gross margin. Management confidently raised full-year gross margin guidance to ~79%. However, beneath the bottom-line strength lies a noticeable deceleration in revenue. Worldwide revenue grew 11.2% YoY to $52.6M, marking the fourth consecutive quarter of slowing growth (down from 24.9% in 25Q1). Achieving the raised FY26 revenue guidance of 14-16% will require a significant re-acceleration in the back half of the year, heavily dependent on new product launches like INTRA Ti and international market adoption.
🐂 Bull Case
Despite management's previous warnings that new product depreciation (like INTRA Ti and Smith & Nephew instrument sets) would drag margins down to 78%, Q1 delivered a robust 79.8%. This prompted an immediate upward revision to the FY26 gross margin target.
After a delayed regulatory rollout in Europe during FY25, International revenue is finally reversing trend, accelerating to 33.9% YoY growth in 26Q1, driven by the launch of iFuse TORQ TNT.
🐻 Bear Case
Worldwide revenue growth has decelerated sequentially from 24.9% a year ago down to 11.2% today. The 'innovation super cycle' has yet to re-accelerate the overall growth rate.
FY26 revenue guidance implicitly requires a second-half acceleration. With Q1 OpEx growing only 4.1% against a full-year guide of 12.5%, the company will need to spend heavily to drive this upcoming volume, risking near-term EBITDA margins.
⚖️ Verdict: ⚪
Neutral. The financial discipline and path to free cash flow generation are stellar. However, the persistent deceleration in revenue growth creates a 'show-me' story for the back half of the year. Investors must weigh excellent margin defense against slowing volume momentum.
Key Themes
Sequential Deceleration in Top-Line Growth
The primary red flag in this report is the continued deceleration in revenue growth. U.S. revenue grew just 10.0% YoY, a sharp drop from the 26.6% growth reported in 25Q1. While absolute revenue dollars are higher, the growth rate has steadily decayed for four straight quarters. Management expects 14-16% growth for the full year, which means the current 11% trajectory must reverse and accelerate sharply in the coming quarters.
International Operations Reversing Course
International sales provided a much-needed bright spot. After sluggish ~10-12% growth rates in late FY25 due to European regulatory delays, International revenue jumped 33.9% YoY to $3.3 million. This acceleration is directly tied to the recent market introductions of iFuse TORQ TNT in Europe and iFuse TORQ in Australia, proving the international appetite for the company's newer form factors.
Macro Tailwinds: CMS Reimbursement Support
A crucial catalyst for the Granite platform materialized: CMS proposed the creation of a new MS-DRG family in the FY2027 IPPS Proposed Rule. This will yield higher payments for hospitals supporting complex spinal fusion procedures using iFuse Bedrock Granite. Better hospital economics directly reduce friction for physician adoption.
Commercial Footprint Reaching Scale
The company's hybrid commercial model remains stable and highly productive. Active U.S. physicians grew 17% to over 1,650, while trailing 12-month average revenue per territory increased 11% to $2.2 million. The ability to simultaneously increase the physician base and extract more revenue per territory proves the cross-selling viability of the multi-product platform (SI joint, pelvic fixation, trauma).
Operating Expense Imbalance vs. Guidance
Operating expenses grew a modest 4.1% in Q1 (to $47.0M), allowing the company to post a strong $2.5M Adjusted EBITDA. However, management maintained its guidance for FY26 OpEx growth of ~12.5%. This heavily implies that spending will accelerate significantly in Q2-Q4 to support the commercial rollout with Smith & Nephew and the INTRA Ti launch, which could temporarily compress the EBITDA margins achieved this quarter.
Other KPIs
Cash burn is decelerating rapidly. While technically negative, this represents a 51% improvement from the -$7.0 million reported in 25Q1. Operating cash usage halved to -$2.4M, and CapEx dropped to -$1.1M. With $144.7M in total cash and equivalents, the balance sheet remains exceptionally strong without the need for near-term dilution.
Stable. The gross margin profile proved highly resilient against prior concerns. In previous quarters, management warned of a medium-term structural step-down to ~76-78% due to non-cash depreciation from new instrument sets (like those needed for the Smith & Nephew partnership). Yet, 26Q1 posted 79.8%, leading to an upward revision in annual guidance.
Guidance
Accelerating vs current run-rate. The midpoint of $231.5M implies ~15% YoY growth. Because Q1 only grew 11.2%, management is explicitly relying on back-half acceleration driven by the Smith & Nephew partnership, INTRA Ti ramp, and favorable CMS decisions.
Improving. Raised from prior guidance of ~78.0%. This is a strong signal that manufacturing efficiencies and product mix (potentially higher ASP from complex cases) are outpacing the drag of depreciation from new instrument deployments.
Accelerating vs Q1. With Q1 OpEx up only 4.1%, the company is signaling that the bulk of its commercial and R&D investments will hit the P&L in the coming quarters.
Key Questions
Bridging the Growth Gap
U.S. revenue growth stepped down to 10% in Q1. Given the FY guidance requires mid-teens growth, exactly how much of the expected back-half acceleration is dependent on the unproven Smith & Nephew partnership versus organic traction of INTRA Ti?
OpEx Phasing
You held OpEx growth to just 4.1% this quarter but maintained a 12.5% full-year guide. In which specific quarters should we expect this investment spike to hit, and is it primarily related to surgical tray CapEx/depreciation or direct headcount additions?
CMS Proposal Timing
Regarding the FY2027 IPPS Proposed Rule for a new MS-DRG family for Granite—how quickly do you anticipate hospitals adjusting their purchasing behavior ahead of the finalization, and is any of this upside modeled into the current 2026 guide?